Transcriptomic FHIT/pHER2 signature as a predictive factor of outcome and immunotherapy response in non-small cell lung cancer.
Fiche publication
Date publication
décembre 2022
Journal
Frontiers in immunology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DALSTEIN Véronique, Pr POLETTE Myriam, Dr NAWROCKI-RABY Béatrice, Pr GERMAIN Adeline, Dr DORMOY Valerian
Tous les auteurs :
Brisebarre A, Ancel J, Ponchel T, Loeffler E, Germain A, Dalstein V, Dormoy V, Durlach A, Delepine G, Deslée G, Polette M, Nawrocki-Raby B
Lien Pubmed
Résumé
In recent decades, the development of immunotherapy and targeted therapies has considerably improved the outcome of non-small cell lung cancer (NSCLC) patients. Despite these impressive clinical benefits, new biomarkers are needed for an accurate stratification of NSCLC patients and a more personalized management. We recently showed that the tumor suppressor fragile histidine triad (FHIT), frequently lost in NSCLC, controls HER2 receptor activity in lung tumor cells and that tumor cells from NSCLC patients harboring a FHIT/pHER2 phenotype are sensitive to anti-HER2 drugs. Here, we sought to identify the transcriptomic signature of this phenotype and evaluate its clinical significance.
Mots clés
FHIT, HER2, NSCLC, immunotherapy response, prognosis, transcriptomic signature
Référence
Front Immunol. 2022 12 5;13:1058531